
• Reported GAAP EPS of -$0.07 down -240.00% YoY • Reported revenue of $58.99M down -33.12% YoY • For 2026, MIMEDX expects net sales in a range of $260 to $290 million and anticipates 2026 Adjusted EBITDA to be approximately breakeven on a full year basis.
Bullish
MIMEDX's Surgical business grew 13% year over year, and the company adjusted its cost structure for $40 million in annualized savings, positioning for profitability and future double-digit growth.
Bearish
MIMEDX faced a 60% decline in its Wound business and gross margin compression due to new Medicare reimbursement policies and inconsistent MAC implementation, leading to a Q1 net loss.